Clinical Trials Office (CTO)
The Clinical Trials Office within the Carole and Ray Neag Comprehensive Cancer Center is focused on supporting high-quality cancer research and thus help promote better care for cancer patients at UConn Health. The staff consists of highly qualified, trained and certified professionals who are committed to assisting in the planning, development, implementation, and regulatory oversight of all phases of cancer clinical trials.
The office was created under the Medical Directorship of Pramod K. Srivastava, Ph.D., M.D., and Director of the Cancer Center and provides a dedicated team to enable Hematology and Medical Oncology faculty to bring to UConn Health, innovative treatment options that otherwise would not be available to cancer patients. The Clinical Trials Office actively partners with various cancer cooperative groups, pharmaceutical firms, and other academic centers to bring revolutionary cancer research studies to UConn Health. By supporting clinical research, the office aids UConn Health to meet its goals of excellence in patient care, education, and research. It also engages with other cancer research programs within UConn Health to reach out to the community to educate patients about clinical trials, create awareness on cancer prevention, and increase patient participation in clinical trials.
Current Membership Status
- Cancer Trials Support Unit (CTSU)
- The Academic and Community Cancer Research United (ACCRU)
Current Therapeutic Studies Opened to Accrual
- Oxbryta® Product Registry an Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD (PROSPECT)
- Forma Therapeutics: An Adaptive, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study of Oral FT-4202, a Pyruvate Kinase Agonist in Subjects With Sickle Cell Disease (PRAISE)
- Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB/II Study
- A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) Versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
- GMCI Plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients LuTK02
- Randomized Controlled Trial Assessing Transperineal Prostate Biopsy to Reduce Infection Complications
- Determination of the Potential Clinical Utility of the QCDx-br™ Liquid Biopsy Technology to Optimize Treatment Options for Breast Cancer Patients
- The Management of Acromegaly (MACRO) Registry
- A Retrospective Data Collection and Analysis Study of Patients with Sickle Cell Disease (SCD) Who Have Been Treated With Oxbryta (Voxelotor)
- An Adaptive, Randomized, Placebo-controlled, Double-blind, Multicenter Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease
Pramod Srivastava, Ph.D., M.D.
Clinical Trials Office Medical Director
Clinical Trials Office Administrative Manager
Quratulain Ali, M.P.H., CCRP, MSHS
Clinical Trials Office Supervisor
Melanie Klinck, LMSW
Clinical Research Associate
Katarzyna Nastri, B.A., CCRP
Clinical Research Associate, Compliance and Quality
Jillian McNamara, B.S., M.P.H.
Clinical Research Assistant
Maria Ortiz, M.P.H., Ph.D. Student
Clinical Research Associate
Administrative Fiscal Assistant
About Clinical Trials
Clinical trials are research studies in which real people participate as volunteers. Clinical research studies (also known as clinical trials) are designed to evaluate health risks and to test new approaches to the diagnosis, treatment and prevention of specific diseases. These studies play a significant role in the development of new treatments and medications for various diseases and conditions. A clinical trial could be a treatment option for you.
The goal of research is to find better ways to treat or identify cancer and help cancer patients. Clinical trials test many types of treatment, such as new drugs, new approaches to surgery or radiation therapy, new combinations of treatments, or new methods such as gene therapy. Some clinical trials study the effects of our standard treatments on patient quality of life during and after completion of the treatment. The knowledge that may be gained from this type of work can be of great value to our society.
To ensure the safety of volunteers who enroll in clinical studies, each project must be approved by an Institutional Review Board (IRB). The goal of the IRB is to ensure safety, welfare and well-being of study participants. During the review process, the IRB evaluates the potential risks and benefits associated with the study and decide whether or not to approve it.
This information is provided by the National Library of Medicine (NLM).